Skip to content
DataLookout
Menu

NCT05677490

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 21 versions: 20 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 798 → 802 locations
  2. Notable Eligibility criteria shortened, about 14 words
    • Trial sites expanded: 793 → 798 locations
    • Secondary endpoints: details revised at 5 of 5 entries
  3. Minor Site details revised at 20 of 793 sitesv19
  4. Notable Eligibility criteria shortened, about 46 words
    • Site details revised at 1 of 793 sites
    v18
  5. Minor Study sites: 794 to 793v17
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 792 to 794v16
  2. Minor Study sites: 791 to 792v15
  1. Minor Trial sites expanded: 786 → 791 locationsv14
  2. Minor Study sites: 783 to 786v13
  3. Minor Study sites: 782 to 783v12
  4. Minor Study sites: 780 to 782v11
  5. Minor Study sites: 778 to 780v10
  6. Minor Study sites: 777 to 778v9
  7. Minor Study sites: 756 to 777v8
  8. Minor Study sites: 735 to 756v7
  9. Minor Start date: Jan 23, 2023 to Jan 31, 2023
    • Site details revised at 690 of 735 sites
    v6
  10. Minor Study sites: 564 to 735v5
  11. Minor Study sites: 548 to 564v4
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 548
    • Start date changed from estimate of Jan 6, 2023 to Jan 23, 2023
    v2
  13. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Overall survival (OS)
Timeframe: Up to 2 years from the time of randomization.

Secondary (5)

Progression-free survival (PFS)
Overall response rate
Duration of Response
Incidence of adverse events
Patient reported outcomes

Arms and interventions

Arm I (mFOLFIRINOX, nivolumab)Experimental

Patients receive fluorouracil IV over 44-46 hours on day 1 of each cycle, leucovorin calcium as bolus injection or IV infusion over 10-120 minutes on day 1 of each cycle, oxaliplatin IV over 2-6 hours on day 1 for up to 12 cycles, and irinotecan IV over 90 minutes on day 1 of each cycle. Patients may also receive nivolumab IV over 30 minutes on day 1 of each cycle as clinically indicated. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI and a CT scan throughout the trial. Patients may also undergo blood sample collection on study.

Arm II (mFOLFOX, nivolumab)Active comparator

Patients receive fluorouracil IV bolus and IV infusion over 44-46 hours on day 1 of each cycle, leucovorin calcium as bolus injection or IV infusion over 10-120 minutes on day 1 of each cycle, and oxaliplatin IV over 2-6 hours on day 1 for up to 12 cycles. Patients may also receive nivolumab IV over 30 minutes on day 1 of each cycle as clinically indicated. Cycles repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo MRI and a CT scan throughout the trial. Patients may also undergo blood sample collection on study. Patients are followed every 6 months until 3 years following registration, or at the time of tumor progression, withdrawal or removal from the study.

Drugs: Fluorouracil, Leucovorin Calcium, Oxaliplatin, Irinotecan

Biologicals: Nivolumab

Procedures: Magnetic Resonance Imaging, Computed Tomography, Biospecimen Collection

Other: Questionnaire Administration

Sites

802 sites in 2 countries

United States 795, Puerto Rico 7